Total Payments
$624,527
2024 Payments
$159,818
Companies
30
Transactions
763
Medicare Patients
1,211
Medicare Billing
$529,906
Payment Breakdown by Category
Other$308,354 (49.4%)
Consulting$221,866 (35.5%)
Travel$72,917 (11.7%)
Food & Beverage$18,079 (2.9%)
Research$3,305 (0.5%)
Education$7.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $261,824 | 97 | 41.9% |
| Consulting Fee | $221,866 | 85 | 35.5% |
| Travel and Lodging | $72,917 | 315 | 11.7% |
| Honoraria | $46,530 | 20 | 7.5% |
| Food and Beverage | $18,079 | 239 | 2.9% |
| Unspecified | $3,305 | 6 | 0.5% |
| Education | $7.00 | 1 | 0.0% |
Payments by Type
General
$621,223
757 transactions
Research
$3,305
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $238,289 | 314 | $0 (2024) |
| Grifols USA, LLC | $181,069 | 197 | $0 (2024) |
| UCB SA | $64,438 | 23 | $0 (2024) |
| ARGENX US, INC. | $39,064 | 48 | $0 (2024) |
| UCB, Inc. | $27,036 | 50 | $0 (2024) |
| Janssen Global Services, LLC | $19,714 | 25 | $0 (2024) |
| Shire North American Group Inc | $11,425 | 22 | $0 (2019) |
| Amgen Inc. | $9,923 | 13 | $0 (2024) |
| CSL Behring | $6,036 | 14 | $0 (2023) |
| Sarepta Therapeutics, Inc. | $5,920 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $159,818 | 191 | Grifols USA, LLC ($58,121) |
| 2023 | $101,406 | 108 | Grifols USA, LLC ($32,628) |
| 2022 | $142,526 | 150 | Alexion Pharmaceuticals, Inc. ($67,823) |
| 2021 | $48,376 | 43 | Alexion Pharmaceuticals, Inc. ($26,664) |
| 2020 | $23,548 | 20 | Alexion Pharmaceuticals, Inc. ($13,353) |
| 2019 | $27,021 | 68 | Grifols USA, LLC ($10,930) |
| 2018 | $67,284 | 102 | Alexion Pharmaceuticals, Inc. ($44,139) |
| 2017 | $54,548 | 81 | Alexion Pharmaceuticals, Inc. ($29,521) |
All Payment Transactions
763 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Enspryng (Biological) | — | In-kind items and services | $1,218.72 | Research |
| Study: Efficacy safety PK PD of satralizumab in patients with generalized Myasthenia Gravis • Category: Immunology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Enspryng (Biological) | — | In-kind items and services | $588.87 | Research |
| Study: Efficacy safety PK PD of satralizumab in patients with generalized Myasthenia Gravis • Category: Immunology | ||||||
| 12/20/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $7,232.00 | General |
| 12/18/2024 | Janssen Global Services, LLC | — | Travel and Lodging | Cash or cash equivalent | $46.69 | General |
| 12/18/2024 | Janssen Global Services, LLC | — | Travel and Lodging | Cash or cash equivalent | $46.35 | General |
| 12/17/2024 | Janssen Global Services, LLC | — | Travel and Lodging | In-kind items and services | $176.10 | General |
| 12/17/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $99.32 | General |
| 12/17/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $38.10 | General |
| 12/17/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $10.81 | General |
| 12/17/2024 | Janssen Global Services, LLC | — | Food and Beverage | In-kind items and services | $9.85 | General |
| 12/16/2024 | Janssen Global Services, LLC | — | Travel and Lodging | In-kind items and services | $176.10 | General |
| 12/16/2024 | Janssen Global Services, LLC | — | Travel and Lodging | Cash or cash equivalent | $6.49 | General |
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Janssen Global Services, LLC | — | Travel and Lodging | In-kind items and services | $6,327.71 | General |
| 12/06/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $901.95 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $188.23 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $25.94 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $8.57 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Travel and Lodging | Cash or cash equivalent | $16.21 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $6.09 | General |
| Category: Neurology | ||||||
| 12/04/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $6.06 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Efficacy safety PK PD of satralizumab in patients with generalized Myasthenia Gravis | F. Hoffmann-La Roche AG | $2,386 | 3 |
| Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia Gravis | Regeneron Pharmaceuticals, Inc. | $376.57 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myasthenia Gravis | EMD Serono, Inc. | $363.84 | 1 |
| Evaluating Efgartigimod in Patients With Guillain-Barr Syndrome | ARGENX US, INC. | $178.53 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 394 | 1,260 | $3.9M | $37,587 |
| 2022 | 7 | 353 | 989 | $1.7M | $30,632 |
| 2021 | 5 | 107 | 542 | $59,994 | $18,806 |
| 2020 | 15 | 357 | 11,918 | $670,697 | $442,881 |
Total Patients
1,211
Total Services
14,709
Medicare Billing
$529,906
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2023 | 102 | 892 | $1.6M | $21,768 | 1.3% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2023 | 41 | 41 | $479,214 | $3,688 | 0.8% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2023 | 104 | 105 | $1.0M | $3,605 | 0.3% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2023 | 44 | 44 | $182,020 | $2,717 | 1.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $4,860 | $2,258 | 46.5% |
| 95870 | Needle measurement of electrical activity in arm, leg, trunk or head muscles, limited study | Facility | 2023 | 35 | 80 | $297,856 | $1,188 | 0.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 13 | 26 | $134,000 | $897.78 | 0.7% |
| 95908 | Nerve conduction, 3-4 studies | Facility | 2023 | 11 | 11 | $32,610 | $549.56 | 1.7% |
| 95822 | Measurement of brain wave activity (eeg), in coma or asleep | Facility | 2023 | 11 | 11 | $33,000 | $474.76 | 1.4% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 15 | 32 | $117,800 | $441.76 | 0.4% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2022 | 91 | 666 | $660,885 | $16,796 | 2.5% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2022 | 45 | 45 | $310,992 | $4,173 | 1.3% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2022 | 87 | 88 | $454,999 | $3,093 | 0.7% |
| 95861 | Needle measurement of electrical activity in arm or leg muscles, 2 extremities | Facility | 2022 | 36 | 36 | $72,000 | $2,298 | 3.2% |
| 95822 | Measurement of brain wave activity (eeg), in coma or asleep | Facility | 2022 | 43 | 43 | $129,000 | $1,914 | 1.5% |
| 95870 | Needle measurement of electrical activity in arm, leg, trunk or head muscles, limited study | Facility | 2022 | 39 | 93 | $93,000 | $1,411 | 1.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 12 | 18 | $1,764 | $948.14 | 53.7% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2021 | 31 | 460 | $26,190 | $11,871 | 45.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $5,130 | $2,917 | 56.9% |
| 95939 | Insertion of needles and skin electrodes for measurement and recording of stimulated sites in the arms and legs (brain motor stimulation) | Facility | 2021 | 16 | 16 | $8,265 | $1,513 | 18.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 13 | 18 | $2,484 | $1,451 | 58.4% |
| 95938 | Insertion of needles and skin electrodes for measurement and recording of stimulated sites in the arms and legs | Facility | 2021 | 28 | 29 | $17,925 | $1,054 | 5.9% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2020 | 11 | 6,300 | $390,600 | $261,186 | 66.9% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2020 | 14 | 4,340 | $212,660 | $141,860 | 66.7% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2020 | 42 | 478 | $15,774 | $12,238 | 77.6% |
About Dr. Gil Wolfe, MD
Dr. Gil Wolfe, MD is a Neurology healthcare provider based in Buffalo, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215995535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gil Wolfe, MD has received a total of $624,527 in payments from pharmaceutical and medical device companies, with $159,818 received in 2024. These payments were reported across 763 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($261,824).
As a Medicare-enrolled provider, Wolfe has provided services to 1,211 Medicare beneficiaries, totaling 14,709 services with total Medicare billing of $529,906. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Buffalo, NY
- Active Since 05/03/2006
- Last Updated 09/02/2021
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1215995535
Products in Payments
- Gamunex-C (Biological) $168,643
- SOLIRIS (Drug) $72,006
- ULTOMIRIS (Biological) $64,591
- Soliris (Drug) $28,925
- SOLIRIS (Biological) $25,718
- VYVGART (Drug) $25,554
- Xembify (Biological) $12,530
- Rystiggo (Drug) $10,911
- VYVGART HYTRULO (Drug) $8,856
- Zilbrysq (Drug) $8,523
- Enspryng (Biological) $7,972
- UPLIZNA (Biological) $6,923
- GAMMAGARD (Biological) $6,194
- Hizentra (Biological) $6,036
- EXONDYS 51 (Drug) $5,741
- UPLIZNA (Drug) $2,700
- GAMMAGARD LIQUID (Biological) $800.00
- NEXVIAZYME (Biological) $255.63
- SPINRAZA (Biological) $155.96
- AUBAGIO (Drug) $114.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Buffalo
David Hojnacki, Md, MD
Neurology — Payments: $633,608
Neurology $633,608
Nicholas Silvestri, M.d, M.D
Neurology — Payments: $628,943
Neurology $628,943
Bianca Weinstock Guttman, Md, MD
Neurology — Payments: $572,843
Neurology $572,843
Dr. Channa Kolb, M.d, M.D
Neurology — Payments: $202,591
Neurology $202,591
Dr. Robert Glover, M.d, M.D
Neurology — Payments: $65,561
Neurology $65,561
Svetlana Eckert, M.d, M.D
Neurology — Payments: $51,514
Neurology $51,514